Paltac (8283) Q4 2025 earnings summary

Executive summary

• Net sales reached a record-high ¥1,188.0bn for FY2025, up 3.1% year-over-year, driven by increased demand for outdoor, inbound tourism, and new products, despite consumer budget-consciousness and higher logistics costs.

• Operating profit rose 3.1% to ¥28.0bn, with profit margin stable at 2.36%; net profit grew 10.8% to ¥22.86bn, reflecting improved gross profit and fixed expense absorption.

• Sales growth was led by daily necessities (+5.0%) and cosmetics (+3.9%), while OTC pharmaceuticals and health/sanitary products declined.

• Drugstores and discount stores were the strongest customer categories, while home centers and export/EC business declined.

• Sales fell slightly short of plan, but operating profit met expectations due to successful profit improvement measures.

Financial highlights

• Net sales rose by ¥36.1bn (+3.1%) year-over-year; operating profit increased by ¥0.8bn (+3.1%).

• Gross profit increased 3.0% to ¥88,982 million; gross margin remained nearly flat at 7.49%.

• SG&A expenses increased by ¥1.7bn, but the ratio to sales improved by 0.01%.

• Cash and cash equivalents at year-end were ¥69.9bn, up ¥8.92bn from the prior year.

• Extraordinary income included a ¥1.01bn gain on sales of investment securities; extraordinary losses declined by ¥1.26bn year-over-year.

Outlook and guidance

• FY2026 net sales projected at ¥1,230.0bn (+3.5%), operating profit at ¥29.0bn (+3.5%), but profit expected to decrease by 3.8% due to higher SG&A and logistics costs.

• Continued dividend increases planned, with FY2026 dividend per share expected to rise by ¥15 to ¥120.

• Capital investment for FY2026 estimated at ¥2.5bn, mainly for leased centers.

• Management aims to improve profitability and capital efficiency under the medium-term plan “PALTAC VISION 2027.”